胃肠道药物市场：按分类、疾病类型、给药途径和最终用户分类 - 全球预测 2023-2030

全球胃肠道药物市场预计将大幅成长，2023年将达到541.8亿美元，2030年将达到803.1亿美元，年复合成长率为5.76%。

FPNV定位矩阵

FPNV定位矩阵对于评估全球胃肠道药物市场至关重要。透过检查业务策略和产品满意度的关键指标，我们对供应商进行全面评估，使您能够根据您的特定需求做出明智的资讯。这种进阶分析将供应商分为四个像限，并取得了不同程度的成功：前沿 (F)、探路者 (P)、利基 (N) 和重要 (V)。

市占率分析

市场占有率分析可以深入了解供应商在特定市场领域的当前地位。比较供应商对总收入、基本客群和其他关键指标的贡献，可以帮助公司更好地了解他们在争夺市场份额时的表现以及面临的情况。该分析还揭示了特定行业的竞争程度、累积和合併的优势以及研究基准年的合併特征。

本报告提供了以下几点见解：

1. 市场渗透率：提供有关主要企业所服务的市场的全面资讯。

2. 市场开发：提供有关利润丰厚的新兴市场的详细资讯，并分析其在成熟市场的渗透率。

3. 市场多元化：提供有关新产品发布、未开发领域、最新发展和投资的详细资讯。

4.市场趋势：全面了解COVID-19、俄罗斯-乌克兰衝突和高通膨的累积影响。

5.竞争评估与资讯：对主要企业的市场占有率、策略、产品、认证、法规状况、专利状况、製造能力等进行综合评估。

6. 产品开发与创新：提供对未来技术、研发活动和突破性产品开发的见解。

本报告回答了以下问题：

1.全球胃肠道药物市场规模及预测如何？

2.在预测期内，COVID-19对全球胃肠道药物市场的阻碍因素和影响为何？

3.在预测期内，全球胃肠道药物市场需要投资哪些产品/细分市场/应用/领域？

4.全球胃肠道药物市场的竞争策略为何？

5.全球胃肠道药物市场的技术趋势与法律规范如何？

6.全球胃肠道药物市场主要厂商的市占率为何？

7. 哪些型态和策略性措施被认为适合进入全球胃肠道市场？

目录

第1章前言

第2章调查方法

第3章执行摘要

第4章市场概况

第5章市场洞察

• 市场动态
  • 促进因素
    • 老年人口增加，生活方式饮食习惯改变
    • 生物製剂的发展和直肠相关疾病的增加
    • 药物开发和意识提高
  • 抑制因素
    • 与药物相关的副作用
  • 机会
    • 加强药物开发的研究和开发活动
    • 治疗过程中的技术进步
  • 任务
    • 发炎性肠道疾病和大肠激躁症等疾病没有永久治疗方法
• 市场趋势
• COVID-19 的累积影响
• 俄罗斯-乌克兰衝突的累积影响
• 高通膨的累积效应
• 波特五力分析
• 价值炼和关键路径分析
• 法律规范
• 客户客製化

第6章胃肠道药物市场（依药品类别）

• 酸中和剂
• 发炎药
• 止吐药和抗噁心药
• 生物製品
• 泻药和止泻药

第7章胃肠道药物市场：依疾病类型

• 食道症
• 大肠激躁症

第8章胃肠道药物市场：依给药途径分类

• 口服
• 胃肠外的
• 直肠

第9章胃肠道药物市场：依最终使用者分类

• 医院药房
• 零售药房

第10章美洲胃肠道药物市场

• 阿根廷
• 巴西
• 加拿大
• 墨西哥
• 美国

第11章亚太胃肠道药物市场

• 澳洲
• 中国
• 印度
• 印尼
• 日本
• 马来西亚
• 菲律宾
• 新加坡
• 韩国
• 台湾
• 泰国
• 越南

第12章欧洲、中东及非洲胃肠道药物市场

• 丹麦
• 埃及
• 芬兰
• 法国
• 德国
• 以色列
• 义大利
• 荷兰
• 奈及利亚
• 挪威
• 波兰
• 卡达
• 俄罗斯
• 沙乌地阿拉伯
• 南非
• 西班牙
• 瑞典
• 瑞士
• 土耳其
• 阿拉伯聯合大公国
• 英国

第13章竞争形势

• FPNV定位矩阵
• 市占率分析：主要企业
• 竞争情境分析：主要企业

第14章上市公司名单

第15章附录

• 讨论指南
• 关于许可证和定价

The Global Gastrointestinal Drugs Market is forecasted to grow significantly, with a projected USD 54.18 billion in 2023 at a CAGR of 5.76% and expected to reach a staggering USD 80.31 billion by 2030.

The Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and High Inflation is expected to have significant long-term effects on the Global Gastrointestinal Drugs Market. The ongoing research considers the changes in consumer behavior, supply chain disruptions, and government interventions caused by the pandemic. Similarly, the report considers the ongoing political and economic uncertainty in Eastern Europe caused by the Russia-Ukraine Conflict and its potential implications for demand-supply balances, pressure on pricing variants, and import/export and trading. Additionally, the report addresses the impact of High Inflation on the global economy and details fiscal policies measuring and reducing its effects on demand, supply, cash flow, and currency exchange.

Market Segmentation & Coverage:

This research report categorizes the Global Gastrointestinal Drugs Market in order to forecast the revenues and analyze trends in each of following sub-markets:

Based on Drug Category, market is studied across Acid Neutralizers, Anti-Inflammatory, Antiemetic & Antinauseants, Biologics, and Laxatives & Anti-diarrheal. The Antiemetic & Antinauseants is projected to witness significant market share during forecast period.

Based on Disease Type, market is studied across Gastroesophageal Reflux Disorder and Irritable Bowel Syndrome. The Irritable Bowel Syndrome is projected to witness significant market share during forecast period.

Based on Route of Administration, market is studied across Oral, Parenteral, and Rectal. The Parenteral is projected to witness significant market share during forecast period.

Based on End User, market is studied across Hospital Pharmacies and Retail Pharmacies. The Hospital Pharmacies is projected to witness significant market share during forecast period.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Asia-Pacific is projected to witness significant market share during forecast period.

Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make well-informed decisions. In this report, 2018 to 2021 are considered as historical years, 2022 is base year, 2023 is estimated year, and years from 2024 to 2030 are considered as forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix is essential for assessing the Global Gastrointestinal Drugs Market. It provides a comprehensive evaluation of vendors by examining key metrics within Business Strategy and Product Satisfaction, allowing users to make informed decisions based on their specific needs. This advanced analysis then organizes these vendors into four distinct quadrants, which represent varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital(V).

Market Share Analysis:

The Market Share Analysis offers an insightful look at the current state of vendors in a particular market space. By comparing vendor contributions to overall revenue, customer base, and other key metrics, we can give companies a greater understanding of their performance and what they are up against when competing for market share. The analysis also sheds light on just how competitive any given sector is about accumulation, fragmentation dominance, and amalgamation traits over the base year period studied.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players

2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets

3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments

4. Market Trends: Provides comprehensive understanding of the Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and the High Inflation

5. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players

6. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Gastrointestinal Drugs Market?

2. What are the inhibiting factors and impact of COVID-19 shaping the Global Gastrointestinal Drugs Market during the forecast period?

3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Gastrointestinal Drugs Market?

4. What is the competitive strategic window for opportunities in the Global Gastrointestinal Drugs Market?

5. What are the technology trends and regulatory frameworks in the Global Gastrointestinal Drugs Market?

6. What is the market share of the leading vendors in the Global Gastrointestinal Drugs Market?

7. What modes and strategic moves are considered suitable for entering the Global Gastrointestinal Drugs Market?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Limitations
• 1.7. Assumptions
• 1.8. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

• 4.1. Introduction
• 4.2. Gastrointestinal Drugs Market, by Drug Category, 2022 vs 2030
• 4.3. Gastrointestinal Drugs Market, by Disease Type, 2022 vs 2030
• 4.4. Gastrointestinal Drugs Market, by Route of Administration, 2022 vs 2030
• 4.5. Gastrointestinal Drugs Market, by End User, 2022 vs 2030
• 4.6. Gastrointestinal Drugs Market, by Region, 2022 vs 2030

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing geriatric population, changing lifestyles and eating habits
    • 5.1.1.2. Development in biologics and a rising number of rectal related diseases
    • 5.1.1.3. Drug development and rising awareness
  • 5.1.2. Restraints
    • 5.1.2.1. Side effects associated with the drugs
  • 5.1.3. Opportunities
    • 5.1.3.1. R&D activities to enhance drug development
    • 5.1.3.2. Technological advancements in the treatment process
  • 5.1.4. Challenges
    • 5.1.4.1. Unavailable permanent cure for diseases such as inflammatory bowel disease and Irritable bowel syndrome
• 5.2. Market Trends
• 5.3. Cumulative Impact of COVID-19
• 5.4. Cumulative Impact of Russia-Ukraine Conflict
• 5.5. Cumulative Impact of High Inflation
• 5.6. Porter's Five Forces Analysis
  • 5.6.1. Threat of New Entrants
  • 5.6.2. Threat of Substitutes
  • 5.6.3. Bargaining Power of Customers
  • 5.6.4. Bargaining Power of Suppliers
  • 5.6.5. Industry Rivalry
• 5.7. Value Chain & Critical Path Analysis
• 5.8. Regulatory Framework
• 5.9. Client Customization

6. Gastrointestinal Drugs Market, by Drug Category

• 6.1. Introduction
• 6.2. Acid Neutralizers
• 6.3. Anti-Inflammatory
• 6.4. Antiemetic & Antinauseants
• 6.5. Biologics
• 6.6. Laxatives & Anti-diarrheal

7. Gastrointestinal Drugs Market, by Disease Type

• 7.1. Introduction
• 7.2. Gastroesophageal Reflux Disorder
• 7.3. Irritable Bowel Syndrome

8. Gastrointestinal Drugs Market, by Route of Administration

• 8.1. Introduction
• 8.2. Oral
• 8.3. Parenteral
• 8.4. Rectal

9. Gastrointestinal Drugs Market, by End User

• 9.1. Introduction
• 9.2. Hospital Pharmacies
• 9.3. Retail Pharmacies

10. Americas Gastrointestinal Drugs Market

• 10.1. Introduction
• 10.2. Argentina
• 10.3. Brazil
• 10.4. Canada
• 10.5. Mexico
• 10.6. United States

11. Asia-Pacific Gastrointestinal Drugs Market

• 11.1. Introduction
• 11.2. Australia
• 11.3. China
• 11.4. India
• 11.5. Indonesia
• 11.6. Japan
• 11.7. Malaysia
• 11.8. Philippines
• 11.9. Singapore
• 11.10. South Korea
• 11.11. Taiwan
• 11.12. Thailand
• 11.13. Vietnam

12. Europe, Middle East & Africa Gastrointestinal Drugs Market

• 12.1. Introduction
• 12.2. Denmark
• 12.3. Egypt
• 12.4. Finland
• 12.5. France
• 12.6. Germany
• 12.7. Israel
• 12.8. Italy
• 12.9. Netherlands
• 12.10. Nigeria
• 12.11. Norway
• 12.12. Poland
• 12.13. Qatar
• 12.14. Russia
• 12.15. Saudi Arabia
• 12.16. South Africa
• 12.17. Spain
• 12.18. Sweden
• 12.19. Switzerland
• 12.20. Turkey
• 12.21. United Arab Emirates
• 12.22. United Kingdom

13. Competitive Landscape

• 13.1. FPNV Positioning Matrix
• 13.2. Market Share Analysis, By Key Player
• 13.3. Competitive Scenario Analysis, By Key Player

14. List of Company Mentioned

15. Appendix

• 15.1. Discussion Guide
• 15.2. License & Pricing

LIST OF FIGURES

• FIGURE 1. GASTROINTESTINAL DRUGS MARKET RESEARCH PROCESS
• FIGURE 2. GASTROINTESTINAL DRUGS MARKET SIZE, 2022 VS 2030
• FIGURE 3. GASTROINTESTINAL DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2022 VS 2030 (%)
• FIGURE 5. GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2022 VS 2030 (%)
• FIGURE 6. GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2022 VS 2030 (%)
• FIGURE 7. GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2022 VS 2030 (%)
• FIGURE 8. GASTROINTESTINAL DRUGS MARKET SIZE, BY REGION, 2022 VS 2030 (%)
• FIGURE 9. GASTROINTESTINAL DRUGS MARKET DYNAMICS
• FIGURE 10. GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 11. GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 12. GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 13. GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 14. AMERICAS GASTROINTESTINAL DRUGS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 15. UNITED STATES GASTROINTESTINAL DRUGS MARKET SIZE, BY STATE, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 16. ASIA-PACIFIC GASTROINTESTINAL DRUGS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 17. EUROPE, MIDDLE EAST & AFRICA GASTROINTESTINAL DRUGS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 18. GASTROINTESTINAL DRUGS MARKET, FPNV POSITIONING MATRIX, 2022
• FIGURE 19. GASTROINTESTINAL DRUGS MARKET SHARE, BY KEY PLAYER, 2022

LIST OF TABLES

• TABLE 1. GASTROINTESTINAL DRUGS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2022
• TABLE 3. GASTROINTESTINAL DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2018-2030 (USD MILLION)
• TABLE 5. GASTROINTESTINAL DRUGS MARKET SIZE, BY ACID NEUTRALIZERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 6. GASTROINTESTINAL DRUGS MARKET SIZE, BY ANTI-INFLAMMATORY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 7. GASTROINTESTINAL DRUGS MARKET SIZE, BY ANTIEMETIC & ANTINAUSEANTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 8. GASTROINTESTINAL DRUGS MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GASTROINTESTINAL DRUGS MARKET SIZE, BY LAXATIVES & ANTI-DIARRHEAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 11. GASTROINTESTINAL DRUGS MARKET SIZE, BY GASTROESOPHAGEAL REFLUX DISORDER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GASTROINTESTINAL DRUGS MARKET SIZE, BY IRRITABLE BOWEL SYNDROME, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 14. GASTROINTESTINAL DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GASTROINTESTINAL DRUGS MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GASTROINTESTINAL DRUGS MARKET SIZE, BY RECTAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 18. GASTROINTESTINAL DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GASTROINTESTINAL DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. AMERICAS GASTROINTESTINAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 21. AMERICAS GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2018-2030 (USD MILLION)
• TABLE 22. AMERICAS GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 23. AMERICAS GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 24. AMERICAS GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 25. ARGENTINA GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2018-2030 (USD MILLION)
• TABLE 26. ARGENTINA GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 27. ARGENTINA GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 28. ARGENTINA GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 29. BRAZIL GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2018-2030 (USD MILLION)
• TABLE 30. BRAZIL GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 31. BRAZIL GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 32. BRAZIL GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 33. CANADA GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2018-2030 (USD MILLION)
• TABLE 34. CANADA GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 35. CANADA GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 36. CANADA GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 37. MEXICO GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2018-2030 (USD MILLION)
• TABLE 38. MEXICO GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 39. MEXICO GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 40. MEXICO GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 41. UNITED STATES GASTROINTESTINAL DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 42. UNITED STATES GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2018-2030 (USD MILLION)
• TABLE 43. UNITED STATES GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 44. UNITED STATES GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 45. UNITED STATES GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 46. ASIA-PACIFIC GASTROINTESTINAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 47. ASIA-PACIFIC GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2018-2030 (USD MILLION)
• TABLE 48. ASIA-PACIFIC GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 49. ASIA-PACIFIC GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 50. ASIA-PACIFIC GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 51. AUSTRALIA GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2018-2030 (USD MILLION)
• TABLE 52. AUSTRALIA GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 53. AUSTRALIA GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 54. AUSTRALIA GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 55. CHINA GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2018-2030 (USD MILLION)
• TABLE 56. CHINA GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 57. CHINA GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 58. CHINA GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 59. INDIA GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2018-2030 (USD MILLION)
• TABLE 60. INDIA GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 61. INDIA GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 62. INDIA GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 63. INDONESIA GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2018-2030 (USD MILLION)
• TABLE 64. INDONESIA GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 65. INDONESIA GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 66. INDONESIA GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 67. JAPAN GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2018-2030 (USD MILLION)
• TABLE 68. JAPAN GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 69. JAPAN GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 70. JAPAN GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 71. MALAYSIA GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2018-2030 (USD MILLION)
• TABLE 72. MALAYSIA GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 73. MALAYSIA GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 74. MALAYSIA GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 75. PHILIPPINES GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2018-2030 (USD MILLION)
• TABLE 76. PHILIPPINES GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 77. PHILIPPINES GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 78. PHILIPPINES GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 79. SINGAPORE GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2018-2030 (USD MILLION)
• TABLE 80. SINGAPORE GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 81. SINGAPORE GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 82. SINGAPORE GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 83. SOUTH KOREA GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2018-2030 (USD MILLION)
• TABLE 84. SOUTH KOREA GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 85. SOUTH KOREA GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 86. SOUTH KOREA GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 87. TAIWAN GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2018-2030 (USD MILLION)
• TABLE 88. TAIWAN GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 89. TAIWAN GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 90. TAIWAN GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 91. THAILAND GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2018-2030 (USD MILLION)
• TABLE 92. THAILAND GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 93. THAILAND GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 94. THAILAND GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 95. VIETNAM GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2018-2030 (USD MILLION)
• TABLE 96. VIETNAM GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 97. VIETNAM GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 98. VIETNAM GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 99. EUROPE, MIDDLE EAST & AFRICA GASTROINTESTINAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 100. EUROPE, MIDDLE EAST & AFRICA GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2018-2030 (USD MILLION)
• TABLE 101. EUROPE, MIDDLE EAST & AFRICA GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 102. EUROPE, MIDDLE EAST & AFRICA GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 103. EUROPE, MIDDLE EAST & AFRICA GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 104. DENMARK GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2018-2030 (USD MILLION)
• TABLE 105. DENMARK GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 106. DENMARK GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 107. DENMARK GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 108. EGYPT GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2018-2030 (USD MILLION)
• TABLE 109. EGYPT GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 110. EGYPT GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 111. EGYPT GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 112. FINLAND GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2018-2030 (USD MILLION)
• TABLE 113. FINLAND GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 114. FINLAND GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 115. FINLAND GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 116. FRANCE GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2018-2030 (USD MILLION)
• TABLE 117. FRANCE GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 118. FRANCE GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 119. FRANCE GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 120. GERMANY GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2018-2030 (USD MILLION)
• TABLE 121. GERMANY GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 122. GERMANY GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 123. GERMANY GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 124. ISRAEL GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2018-2030 (USD MILLION)
• TABLE 125. ISRAEL GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 126. ISRAEL GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 127. ISRAEL GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 128. ITALY GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2018-2030 (USD MILLION)
• TABLE 129. ITALY GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 130. ITALY GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 131. ITALY GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 132. NETHERLANDS GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2018-2030 (USD MILLION)
• TABLE 133. NETHERLANDS GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 134. NETHERLANDS GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 135. NETHERLANDS GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 136. NIGERIA GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2018-2030 (USD MILLION)
• TABLE 137. NIGERIA GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 138. NIGERIA GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 139. NIGERIA GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 140. NORWAY GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2018-2030 (USD MILLION)
• TABLE 141. NORWAY GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 142. NORWAY GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 143. NORWAY GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 144. POLAND GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2018-2030 (USD MILLION)
• TABLE 145. POLAND GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 146. POLAND GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 147. POLAND GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 148. QATAR GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2018-2030 (USD MILLION)
• TABLE 149. QATAR GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 150. QATAR GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 151. QATAR GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 152. RUSSIA GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2018-2030 (USD MILLION)
• TABLE 153. RUSSIA GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 154. RUSSIA GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 155. RUSSIA GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 156. SAUDI ARABIA GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2018-2030 (USD MILLION)
• TABLE 157. SAUDI ARABIA GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 158. SAUDI ARABIA GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 159. SAUDI ARABIA GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 160. SOUTH AFRICA GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2018-2030 (USD MILLION)
• TABLE 161. SOUTH AFRICA GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 162. SOUTH AFRICA GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 163. SOUTH AFRICA GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 164. SPAIN GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2018-2030 (USD MILLION)
• TABLE 165. SPAIN GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 166. SPAIN GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 167. SPAIN GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 168. SWEDEN GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2018-2030 (USD MILLION)
• TABLE 169. SWEDEN GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 170. SWEDEN GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 171. SWEDEN GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 172. SWITZERLAND GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2018-2030 (USD MILLION)
• TABLE 173. SWITZERLAND GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 174. SWITZERLAND GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 175. SWITZERLAND GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 176. TURKEY GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2018-2030 (USD MILLION)
• TABLE 177. TURKEY GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 178. TURKEY GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 179. TURKEY GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 180. UNITED ARAB EMIRATES GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2018-2030 (USD MILLION)
• TABLE 181. UNITED ARAB EMIRATES GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 182. UNITED ARAB EMIRATES GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 183. UNITED ARAB EMIRATES GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 184. UNITED KINGDOM GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2018-2030 (USD MILLION)
• TABLE 185. UNITED KINGDOM GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 186. UNITED KINGDOM GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 187. UNITED KINGDOM GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 188. GASTROINTESTINAL DRUGS MARKET, FPNV POSITIONING MATRIX, 2022
• TABLE 189. GASTROINTESTINAL DRUGS MARKET SHARE, BY KEY PLAYER, 2022
• TABLE 190. GASTROINTESTINAL DRUGS MARKET LICENSE & PRICING